Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 23649043)

1.

Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.

Wahid R, Simon JK, Picking WL, Kotloff KL, Levine MM, Sztein MB.

Clin Immunol. 2013 Jul;148(1):35-43. doi: 10.1016/j.clim.2013.03.009. Epub 2013 Mar 26.

2.

Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.

Simon JK, Wahid R, Maciel M Jr, Picking WL, Kotloff KL, Levine MM, Sztein MB.

Vaccine. 2009 Jan 22;27(4):565-72. doi: 10.1016/j.vaccine.2008.10.081. Epub 2008 Nov 18.

3.

Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.

Simon JK, Maciel M Jr, Weld ED, Wahid R, Pasetti MF, Picking WL, Kotloff KL, Levine MM, Sztein MB.

Clin Immunol. 2011 May;139(2):185-92. doi: 10.1016/j.clim.2011.02.003. Epub 2011 Mar 8.

4.

Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.

Heine SJ, Diaz-McNair J, Martinez-Becerra FJ, Choudhari SP, Clements JD, Picking WL, Pasetti MF.

Vaccine. 2013 Jun 19;31(28):2919-29. doi: 10.1016/j.vaccine.2013.04.045. Epub 2013 May 2.

5.
6.

Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.

Oaks EV, Turbyfill KR.

Vaccine. 2006 Mar 20;24(13):2290-301. Epub 2005 Dec 5.

PMID:
16364513
7.

Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.

Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, van de Verg L, Walker R, Picking WL, Pasetti MF.

J Immunol. 2014 Feb 15;192(4):1630-40. doi: 10.4049/jimmunol.1302743. Epub 2014 Jan 22.

8.

Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.

Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM.

Vaccine. 1995 Apr;13(5):495-502.

PMID:
7639017
10.

Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.

Shim DH, Chang SY, Park SM, Jang H, Carbis R, Czerkinsky C, Uematsu S, Akira S, Kweon MN.

Vaccine. 2007 Jun 15;25(25):4828-36. Epub 2007 Apr 20.

PMID:
17507120
11.

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.

Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R; Israel Shigella Study Group.

Pediatr Infect Dis J. 2003 Aug;22(8):701-6.

PMID:
12913770
12.

Broadly protective Shigella vaccine based on type III secretion apparatus proteins.

Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL.

Infect Immun. 2012 Mar;80(3):1222-31. doi: 10.1128/IAI.06174-11. Epub 2011 Dec 27.

13.

Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.

Van De Verg LL, Bendiuk NO, Kotloff K, Marsh MM, Ruckert JL, Puryear JL, Taylor DN, Hartman AB.

Vaccine. 1996 Aug;14(11):1062-8.

PMID:
8879103
14.
15.

Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.

Cohen D, Orr N, Robin G, Slepon R, Ashkenazi S, Ashkenazi I, Shemer J.

Clin Diagn Lab Immunol. 1996 Jul;3(4):451-5.

16.

Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.

Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL.

Infect Immun. 2013 Dec;81(12):4470-7. doi: 10.1128/IAI.00859-13. Epub 2013 Sep 23.

17.

Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Kotloff KL, Herrington DA, Hale TL, Newland JW, Van De Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM.

Infect Immun. 1992 Jun;60(6):2218-24.

18.

Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.

Vaccine. 2011 Sep 16;29(40):7009-19. doi: 10.1016/j.vaccine.2011.07.033. Epub 2011 Jul 23.

PMID:
21787825
19.
20.

Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella.

Martinez-Becerra FJ, Scobey M, Harrison K, Choudhari SP, Quick AM, Joshi SB, Middaugh CR, Picking WL.

Vaccine. 2013 May 31;31(24):2667-72. doi: 10.1016/j.vaccine.2013.04.012. Epub 2013 Apr 16.

PMID:
23602665
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk